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Sincluding detailed histologic, gene, and protein expression
profiles of explanted valves, will allow additional insight
into cellular and molecular mechanisms of the observed in
vivo remodeling of engineered heart valves. Additionally,
we plan rigorous evaluation of valves constructed identi-
cally, followed by bioreactor conditioning. Although im-
portant questions remain regarding the types of scaffold
materials and seeded cell types optimally used for heart valve
tissue engineering, the knowledge gained from the current
experiments will guide the next generation of valve design
criteria and future progress toward engineered valves for
pediatric application.20
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Dr Sunjay Kaushal (Chicago, Ill). I really enjoyed that talk. I
know these are very difficult experiments to perform. Could you
provide more details on the histology? For instance, was there
actual elastin formation at 20 weeks or how was the collagen
organized?
Dr Gottlieb. At this point we have hypotheses but no evidence,
and we are involved in detailed investigation of these specific
topics, including the presence or absence of elastin at all time points
and a description of the evolution of collagen in explanted tissues,
including collagen maturity and fiber orientation. Unfortunately, I
do not have those data available today.
Dr Kaushal. Was there growth in these valves over time? I
know it is a short period of time, but any hints that the valves
were growing?
DrGottlieb.We still are limited by sample size. Although this is
a large number of sheep for a preclinical study, we are still limited
by the statistical power of small samples. Therefore, we saw no dif-
ference between the time of implant and the time of explant over 20
weeks. However, we started with conduits that were oversized for
the native pulmonary artery, and by the time the 20-week implants
occurred, the native artery diameter and the conduit diameter were
matched. We did not observe a time point at which there would be
wall stress on the tissue-engineered conduit, which might result in
growth.
Dr Michael E. Jessen (Dallas, Tex). How much growth was
there in the animal? What kind of weight gain did it have over
the 20 weeks?
DrGottlieb.We implanted at 20 kg and explanted at 40 to 45 kg.
Dr. Jessen. So they doubled in size over that time interval?
Dr Gottlieb. That’s right.
Dr Jessen. Did you make any measurements of what happened
to the actual scaffolding material, the polyglycolic acid or the poly-
L-lactic acid?
Dr Gottlieb. That is an important point, particularly in light of
the area of the leaflet decreasing over time. We wonder whether
this represents loss of polymer, extracellular matrix, and/or cells,
or whether it represents a contraction or shrinkage of the tissue
and a stable number of fibers of the bioresorbable scaffolds that
are compressed into a smaller area. These are questions that will un-
dergo investigation in the short term.
Dr David Kalfa (Marseille, France). I really congratulate you
for this work, and I have 2 questions for you. First, concerningery c March 2010
Gottlieb et al Evolving Technology/Basic Sciencethe extracellular matrix Dr Kaushal just spoke about, did you eval-
uate the presence of elastic fibers in the extracellular matrix, at least
on a qualitative way, while waiting for detailed investigation to be
performed? Second, were you interested in cellular tracking?
Dr Gottlieb. Both are excellent questions. The elastin question I
have already spoken to.We do not have the complete data set yet on
elastin in all explanted tissues at all time points, so I am reluctant
to give information. But our preliminary data did not show much
elastin.
In terms of your second question about tracking cells, in our lab-
oratory previously there were experiments with small-scale scaf-
folds that were engineered into patches in which cells were
tracked. We have undertaken some other experiments on a mouse
scale where we can track cells using GFP labels. However, in our
sheep model, we require that the valved conduits produce sufficient
extracellular matrix to be hemostatic when implanted into the circu-
lation. It is established that introduction of labeling vectors can
cause changes in expression of a lot of different genes, not just in
the addition of a label. After transfecting our bone marrow–derived
MSCs with a GFP label, they made insufficient matrix to be hemo-
static in the circulation. Because of this limitation, labeled valved
conduits were unable to withstand pulmonary pressure. As a result,
we have not undertaken those projects because we have not found
a way yet to durably and accurately label cells in a large animal
analogous model.
Dr John S. Ikonomidis (Charleston, SC). These results are
clearly very encouraging because they illustrate the application of
some difficult technology, but at the same time they are disappoint-
ing because of the observation of failure of these conduits after only
20 weeks. My first question is, have you followed these animals out
longer to track the progression of conduit failure?
Second, can you speculate whether cations will be required to
prolong conduit durability?
DrGottlieb.Those are tough questions. To the first one, our lon-
gest duration in our laboratory to date has been 20 weeks, which is 5The Journal of Thoracic and Camonths. We see sufficient pulmonary regurgitation at that point to
end experiments. We see right ventricular dilation, so evidence of
relatively long-term valve regurgitation. We have not monitored
them longer than that. We are hopeful that we will have valve leaf-
lets that function better in the future, and we will then undertake
those longer-term experiments.
In terms of the disappointment associated with failure of the
valves, I think we can only make progress through an iterative pro-
cess in which we look at the modes of failure in an engineering ap-
proach. Our first analysis now is to try to understand what went
wrong. Our second move would be to identify the biology resulting
in valve failure, then to manipulate it in vitro, and then to try it again
in vivo.
Dr Jolanda Kluin (Utrecht, The Netherlands). Could you
briefly compare your results with the results of the 2000 paper by
Simon Hoerstrup of your institution?
Dr Gottlieb. Dr Hoerstrup’s work involved a polymer of poly-
glycolic acid that was dip coated in poly-4-hydroxybutyrate and
seeded with vascular cells. They were completely differentiated
cells from the carotid artery smooth muscle cells and endothelial
cells. To start, we had completely different models, both in terms
of scaffold polymer and in terms of cell. These variables are non-
trivial and can account for many differences that we have seen in
our preliminary analysis of these valves. His experiments involved
6 animals, 1 at each of 6 different time points. Our current experi-
ment is different because it involves a greater number of animals at
multiple time points. His was the proof-of-concept experiment; our
current work represents the test of statistical reproducibility. In the
current experiments, we have seen evidence of valve regurgitation,
which was potentially similar to the central valvular regurgitation,
mentioned but not quantitated in the Hoerstrup paper. This builds
on that work or the model that was established in that work with
different cell types and different scaffolds.
In terms of histology, we will have an opportunity to do a very
in-depth analysis and to report those results separately.rdiovascular Surgery c Volume 139, Number 3 731
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